Investment
Features
FeesSafety
Academy
More
Pluang+

Compare National Beverage Corp. (FIZZ) vs GSK plc (GSK) Price & Performance

National Beverage Corp.Trade

Price performance (Past 24H)

Key statistics

National Beverage Corp. vs GSK plc — how do they compare? National Beverage Corp. trades at $30.69 (market cap $2.89B), while GSK plc trades at $50.43 (market cap $102.60B). The key difference: GSK plc is far larger — about 35.5× National Beverage Corp.'s market cap, and GSK plc pays a 3.57% dividend while National Beverage Corp. pays none. Which is the better fit depends on your goals.

FIZZGSK
Market Cap
$2.89B$102.60B
Sector
Consumer CyclicalHealth
52-Week High
$46.75$61.18
52-Week Low
$30.53$38.22
Enterprise Value
$2.60B$123.04B
Dividend Yield
3.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

National Beverage Corp.

FIZZ trades at $30.60, down 1.42% on the day, with bearish technical signals dominating. The stock shows mixed fundamentals with strong profitability metrics including 37% gross margins and 34% ROE, but faces growth challenges as revenue has stagnated around $1.2B annually. Recent earnings have missed expectations in three of the last four quarters, while the company maintains dividend payments with a recent $3.25 special dividend declaration.

The outlook remains cautious given stalled revenue growth and bearish analyst sentiment with 50% sell ratings. While valuation appears reasonable at 15.7x P/E, competitive pressures in the sparkling water market and declining LaCroix volumes present significant headwinds. The stock's current technical weakness near support levels suggests continued pressure unless fundamental catalysts emerge.

GSK plc

GSK trades at $50.30, down 3.57% today, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates of $1.27, and announced a $2.52 billion cost-saving plan through 2029. Revenue growth remains steady at 5% constant currency, supported by vaccines and specialty medicines. Analyst consensus shows 31% buy ratings with 55% hold, indicating cautious optimism.

GSK's solid profitability and strategic cost initiatives support long-term growth, but near-term stock performance faces headwinds from bearish technicals and mixed analyst sentiment. Key risks include pipeline execution and regulatory challenges, while institutional ownership trends and recent FDA approvals provide stability. The current valuation at 16.02 P/E offers reasonable entry for patient investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About National Beverage Corp.

National Beverage Corp is one of the top 10 non-alcoholic beverage companies in the U.S. Its portfolio skews toward functional drinks (that is those purporting to offer health benefits) and is anchored by the popular LaCroix sparkling water trademark. Other offerings include Rip It energy drinks, Everfresh juices, and soda brands like Shasta and Faygo. The firm controls most of its production and distribution apparatus, with very little outsourcing. In terms of go-to-market, it uses warehouse distribution for big-box retailers, direct-store-delivery for convenience stores and other small outlets, and food-service distributors for the food-service channel (schools, hospitals, restaurants). It is controlled by chairman and CEO Nick Caporella, who owns over 73% of the common stock.

Read more on FIZZ

About GSK plc

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.

Read more on GSK